Sun Pharma, ICGEB to develop dengue vaccine

“Our new collaboration with ICGEB for developing an affordable dengue vaccine is part of our broader commitment for developing new and improved vaccines and drugs against flaviviruses that are of significant health importance to India and rest of the world,” said Kirti Ganorkar, Executive Vice President and Head, Global Business Development, Sun Pharma. “Our decision to partner with ICGEB on dengue vaccine programme followed extensive due diligence and expert consultations on existing dengue vaccine programmes globally,” Ganorkar noted. The announcement comes even as the world’s first dengue vaccine, manufactured by Sanofi Pasteur, the vaccine unit of the French pharmaceutical company Sanofi, awaits approval in India. Sanofi Pasteur’s dengue vaccine has received approval in 11 countries so far Non-profit research organisation ICGEB has conducted pre-clinical studies over the past seven years and developed the existing know-how and patents for the novel dengue vaccine candidate.  “Our pre-clinical data is very encouraging and this could be an ideal dengue vaccine candidate for all target populations,” Dinakar Salunke, Director, ICGEB, said. This is the second collaboration between Sun Pharma and ICGEB focusing on dengue. The first one, announced in May 2016, was related to developing a botanical drug for treatment of dengue.